Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels.
Qianyi Ma, Ayse B Ozel, Shweta Ramdas...
https://pubmed.ncbi.nlm.nih.gov/25208887/Actively Recruiting
Led by Indiana Hemophilia &Thrombosis Center, Inc. · Updated on 2026-06-04
100
Participants Needed
35
Research Sites
21 weeks
Total Duration
Researchers are conducting an international retrospective and prospective study to better understand hyposplasminogenemia, a condition caused by plasminogen deficiency. This study aims to define the natural history of the disease, explore the variability in how it presents in different people, identify markers that predict disease progression, and help develop improved treatments. The research is being conducted across two main centers in the Americas and Europe, gathering data from affected individuals and their first-degree family members. The study will collect both retrospective data from the past year and prospective data for three years on approximately 100 affected individuals and about 500 family members. Biological samples such as DNA and plasma will be collected and analyzed centrally in Italy, except for urine samples that will be analyzed locally. The study will test plasminogen activity and antigen levels, genetic mutations, and other factors influencing disease expression. Follow-up will include in-person visits at the start and end of the study, with telephone check-ins every six months and unscheduled visits as needed based on clinical care. Participants will be involved in providing samples and clinical information at baseline and at the end of their three-year study period. The researchers will monitor disease progression and gather data through regular telephone follow-ups and clinical visits. The main outcomes measured include the natural history of plasminogen deficiency, factors influencing disease severity, and the creation of a biobank for future research. The study is designed to improve understanding of this rare condition over a long-term observation period.
CONDITIONS
Study of Individuals Affected With Hypoplasminogenemia
A
Amy D Shapiro, MD
C
Charles Nakar, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Indiana Hemophilia &Thrombosis Center, Inc.
Lead Sponsor
Fondazione Angelo Bianchi Bonomi
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for consent and eligibility confirmation
Duration - 3 years
Participants are observed to define the natural history of plasminogen deficiency and identify factors related to disease expression and severity. Data and samples are collected over time.
In-person visits at baseline and end of study, plus telephone follow-ups every 6 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Qianyi Ma, Ayse B Ozel, Shweta Ramdas...
https://pubmed.ncbi.nlm.nih.gov/25208887/V Schuster, B Hügle, K Tefs
https://pubmed.ncbi.nlm.nih.gov/17900274/Tiraje Celkan
https://pubmed.ncbi.nlm.nih.gov/27629020/Amy D Shapiro, Marzia Menegatti, Roberta Palla...
https://pubmed.ncbi.nlm.nih.gov/32001536/R C Tait, I D Walker, J A Conkie...
https://pubmed.ncbi.nlm.nih.gov/1455395/Amy D Shapiro, Charles Nakar, Joseph M Parker...
https://pubmed.ncbi.nlm.nih.gov/29321155/Yaqiu Sang, Marzia Menegatti, Jennifer A Brody...
https://pubmed.ncbi.nlm.nih.gov/40403316/Indiana Hemophilia &Thrombosis Center, Inc.
Lead Sponsor
Fondazione Angelo Bianchi Bonomi
Collaborating Sponsor